Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Japanese Patients with CAPS
NCT00991146Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Primary completion
- Feb 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in Cryopyrin-associated periodic syndromes (CAPS), sponsored by Novartis. Started Oct 2009; status: completed.
02
Drugs
canakinumab
03
Conditions
Cryopyrin-associated periodic syndromes (CAPS)
Beyond the preview
Go deeper on NCT00991146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991146.